Overview GA YAZ ACNE in China Phase III Status: Completed Trial end date: 2010-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles. Phase: Phase 3 Details Lead Sponsor: BayerTreatments: Contraceptive AgentsContraceptives, OralDrospirenoneEthinyl Estradiol